病毒性肝炎与肝细胞癌：病因与管理
Viral hepatitis and hepatocellular carcinoma: etiology and management.
作者信息
Zamor Philippe J, deLemos Andrew S, Russo Mark W
机构信息
Division of Hepatology, Carolinas Medical Center, Charlotte, USA.
出版信息
J Gastrointest Oncol. 2017 Apr;8(2):229-242. doi: 10.21037/jgo.2017.03.14.
Abstract
Chronic hepatitis B virus (HBV) and chronic hepatitis C virus (HCV) are associated with hepatic fibrosis and development of hepatocellular carcinoma (HCC). There are differences and variation with the incidence of HCC worldwide. Additionally, HCC develops via different pathways with these viral hepatitides. This review outlines the various mechanisms and pathophysiology that contributes to this process. There will also be a review on the recommended screening for HCC. Treatment considerations, which are different for these viruses, will be outlined in this review.
摘要
慢性乙型肝炎病毒（HBV）和慢性丙型肝炎病毒（HCV）与肝纤维化及肝细胞癌（HCC）的发生相关。全球范围内HCC的发病率存在差异和变化。此外，HCC通过这些病毒性肝炎的不同途径发展而来。本综述概述了促成这一过程的各种机制和病理生理学。还将对推荐的HCC筛查进行综述。本综述将概述针对这些病毒的不同治疗考量。
相似文献
1
Viral hepatitis and hepatocellular carcinoma: etiology and management.病毒性肝炎与肝细胞癌：病因与管理
J Gastrointest Oncol. 2017 Apr;8(2):229-242. doi: 10.21037/jgo.2017.03.14.
2
Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada.加拿大丙型肝炎患者持续病毒学应答对肝细胞癌的长期影响。
J Hepatol. 2017 Mar;66(3):504-513. doi: 10.1016/j.jhep.2016.10.028. Epub 2016 Nov 4.
3
Development and surveillance of hepatocellular carcinoma in patients with sustained virologic response after antiviral therapy for chronic hepatitis C.慢性丙型肝炎抗病毒治疗后获得持续病毒学应答患者的肝细胞癌的发生和监测。
Clin Mol Hepatol. 2019 Sep;25(3):234-244. doi: 10.3350/cmh.2018.0108. Epub 2019 Jan 21.
4
Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication.丙型肝炎病毒清除后，晚期纤维化患者肝硬化相关并发症的风险。
J Hepatol. 2017 Mar;66(3):485-493. doi: 10.1016/j.jhep.2016.10.017. Epub 2016 Oct 22.
5
What Comes First: Treatment of Viral Hepatitis or Liver Cancer?先治肝炎还是先治肝癌？
Dig Dis Sci. 2019 Apr;64(4):1041-1049. doi: 10.1007/s10620-019-05518-5.
6
Differences in background characteristics of patients with chronic hepatitis C who achieved sustained virologic response with interferon-free versus interferon-based therapy and the risk of developing hepatocellular carcinoma after eradication of hepatitis C virus in Japan.在日本，接受无干扰素治疗与基于干扰素治疗并实现持续病毒学应答的慢性丙型肝炎患者的背景特征差异，以及丙型肝炎病毒根除后发生肝细胞癌的风险。
J Viral Hepat. 2017 Jun;24(6):472-476. doi: 10.1111/jvh.12665. Epub 2017 Jan 11.
7
Clinicopathologic characteristics andoutcomes of hepatocellular carcinoma associated with chronic hepatitis B versus hepatitis C infection.慢性乙型肝炎与丙型肝炎感染相关肝细胞癌的临床病理特征及预后
Ann Saudi Med. 2018 Sep-Oct;38(5):358-365. doi: 10.5144/0256-4947.2018.358.
8
Hepatitis C virus in chronic liver disease and hepatocellular carcinoma in Taiwan.台湾慢性肝病与肝细胞癌中的丙型肝炎病毒
Princess Takamatsu Symp. 1995;25:27-32.
9
Sustained virologic response to direct-acting antiviral agents predicts better outcomes in hepatitis C virus-infected patients: A retrospective study.直接作用抗病毒药物的持续病毒学应答可预测丙型肝炎病毒感染患者的更好结局：一项回顾性研究。
World J Gastroenterol. 2019 Oct 28;25(40):6094-6106. doi: 10.3748/wjg.v25.i40.6094.
10
Patterns of hepatocellular carcinoma development in hepatitis B virus and hepatitis C virus related cirrhosis.乙型肝炎病毒和丙型肝炎病毒相关肝硬化中肝细胞癌的发生模式
Antiviral Res. 2001 Nov;52(2):199-207. doi: 10.1016/s0166-3542(01)00185-1.
引用本文的文献
1
Combining serologic biomarkers with the PAGE B score improves risk stratification for hepatocellular carcinoma development among chronic hepatitis B patients.将血清学生物标志物与PAGE B评分相结合可改善慢性乙型肝炎患者发生肝细胞癌的风险分层。
Sci Rep. 2025 Aug 26;15(1):31471. doi: 10.1038/s41598-025-16059-5.
2
Antibody treatment of hepatocellular carcinoma: a review of current and emerging approaches.肝细胞癌的抗体治疗：当前及新兴方法综述
Front Immunol. 2025 Jun 20;16:1533874. doi: 10.3389/fimmu.2025.1533874. eCollection 2025.
3
Efficacy and safety of TACE combined with lenvatinib and PD-1 Inhibitor in intermediate-stage HCC exceeding the up-7 criteria: a retrospective cohort study.经动脉化疗栓塞术联合乐伐替尼和程序性死亡受体1抑制剂治疗超过up-7标准的中期肝细胞癌的疗效与安全性：一项回顾性队列研究
Front Immunol. 2025 Jun 12;16:1560750. doi: 10.3389/fimmu.2025.1560750. eCollection 2025.
4
Gut Microbiota and the Gut-Liver Axis in Liver Disease: From Chronic Viral Hepatitis to Cirrhosis, Hepatocellular Carcinoma, and Microbiome-Based Therapies.肠道微生物群与肝脏疾病中的肠-肝轴：从慢性病毒性肝炎到肝硬化、肝细胞癌及基于微生物群的治疗方法
Microorganisms. 2025 Apr 30;13(5):1053. doi: 10.3390/microorganisms13051053.
5
Antenatal Screening for Hepatitis B Virus in Uganda: Missed Opportunities for Diagnosis and Treatment.乌干达的乙型肝炎病毒产前筛查：诊断和治疗的错失机会
Open Forum Infect Dis. 2025 Mar 10;11(Suppl 3):S193-S199. doi: 10.1093/ofid/ofae603. eCollection 2024 Dec.
6
Hepatitis B virus as a risk factor for hepatocellular carcinoma: There is still much work to do.乙型肝炎病毒作为肝细胞癌的一个风险因素：仍有许多工作要做。
Liver Res. 2024 Jun 1;8(2):83-90. doi: 10.1016/j.livres.2024.05.004. eCollection 2024 Jun.
7
Etiology-Dependent Microbiome Differences in Hepatocellular Carcinoma Development.肝细胞癌发生过程中病因依赖的微生物组差异
Int J Mol Sci. 2024 Dec 17;25(24):13510. doi: 10.3390/ijms252413510.
8
[Not Available].[无可用内容]。
Med Trop Sante Int. 2024 Jul 18;4(3). doi: 10.48327/mtsi.v4i3.2024.418. eCollection 2024 Sep 30.
9
Socioeconomic determinants of malaria and hepatitis infections: insights from the Federal Medical Center, Makurdi, North Central, Nigeria.社会经济因素对疟疾和肝炎感染的影响：来自尼日利亚中北部马库尔迪联邦医疗中心的见解。
BMC Public Health. 2024 Nov 16;24(1):3187. doi: 10.1186/s12889-024-20666-8.
10
Deciphering the multifaceted role of microRNAs in hepatocellular carcinoma: Integrating literature review and bioinformatics analysis for therapeutic insights.解读微小RNA在肝细胞癌中的多方面作用：整合文献综述与生物信息学分析以获取治疗见解
Heliyon. 2024 Oct 18;10(20):e39489. doi: 10.1016/j.heliyon.2024.e39489. eCollection 2024 Oct 30.
本文引用的文献
1
Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection.直接抗病毒药物的持续病毒学应答可降低 HCV 感染患者肝癌的发生率。
J Med Virol. 2017 Mar;89(3):476-483. doi: 10.1002/jmv.24663. Epub 2016 Aug 23.
2
Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals.直接作用抗病毒药物治疗的丙型肝炎相关肝硬化中肝细胞癌的早期发生和复发。
J Hepatol. 2016 Oct;65(4):727-733. doi: 10.1016/j.jhep.2016.06.015. Epub 2016 Jun 24.
3
Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts.直接作用抗病毒药物对肝细胞癌复发影响的证据不足：来自三个法国国家研究署队列的数据。
J Hepatol. 2016 Oct;65(4):734-740. doi: 10.1016/j.jhep.2016.05.045. Epub 2016 Jun 7.
4
Epidemiology of Hepatocellular Carcinoma in the Asia-Pacific Region.亚太地区肝细胞癌的流行病学
Gut Liver. 2016 May 23;10(3):332-9. doi: 10.5009/gnl15257.
5
Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy.接受无干扰素治疗的丙型肝炎相关 HCC 患者早期肿瘤复发率高。
J Hepatol. 2016 Oct;65(4):719-726. doi: 10.1016/j.jhep.2016.04.008. Epub 2016 Apr 13.
6
Mechanisms of HBV-induced hepatocellular carcinoma.HBV 诱导肝细胞癌的机制。
J Hepatol. 2016 Apr;64(1 Suppl):S84-S101. doi: 10.1016/j.jhep.2016.02.021.
7
The hepatitis delta virus: Replication and pathogenesis.丁型肝炎病毒：复制与发病机制。
J Hepatol. 2016 Apr;64(1 Suppl):S102-S116. doi: 10.1016/j.jhep.2016.02.013.
8
Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial.雷迪帕韦和索非布韦联合利巴韦林治疗基因型 1 或 4 型丙型肝炎病毒感染和晚期肝病患者：一项多中心、开放标签、随机、2 期临床试验。
Lancet Infect Dis. 2016 Jun;16(6):685-697. doi: 10.1016/S1473-3099(16)00052-9. Epub 2016 Feb 18.
9
Long-Term Outcomes of Hepatitis-C-Infected Patients Achieving a Sustained Virological Response and Undergoing Radical Treatment for Hepatocellular Carcinoma.丙型肝炎感染患者实现持续病毒学应答并接受肝细胞癌根治性治疗的长期预后
Oncology. 2016;90(3):167-75. doi: 10.1159/000443891. Epub 2016 Feb 23.
10
Achieving sustained virologic response after interferon-free hepatitis C virus treatment correlates with hepatic interferon gene expression changes independent of cirrhosis.无干扰素丙型肝炎病毒治疗后实现持续病毒学应答与肝脏干扰素基因表达变化相关，且与肝硬化无关。
J Viral Hepat. 2016 Jul;23(7):496-505. doi: 10.1111/jvh.12510. Epub 2016 Feb 3.
Zotero 插件